Acitretin - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for acitretin and what is the scope of patent protection?
Acitretin
is the generic ingredient in two branded drugs marketed by Alembic, Barr Labs Inc, Impax Labs Inc, Mylan, Norvium Bioscience, Sigmapharm Labs Llc, Teva Pharms Usa, and Stiefel Labs Inc, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.There are eleven drug master file entries for acitretin. Eight suppliers are listed for this compound.
Summary for acitretin
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 8 |
NDAs: | 8 |
Drug Master File Entries: | 11 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 37 |
Patent Applications: | 6,746 |
Drug Prices: | Drug price trends for acitretin |
What excipients (inactive ingredients) are in acitretin? | acitretin excipients list |
DailyMed Link: | acitretin at DailyMed |
Recent Clinical Trials for acitretin
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Singapore General Hospital | Phase 4 |
Translational Immunology Institute | Phase 4 |
South Valley University | Phase 4 |
Pharmacology for acitretin
Drug Class | Retinoid |
Medical Subject Heading (MeSH) Categories for acitretin
Anatomical Therapeutic Chemical (ATC) Classes for acitretin
US Patents and Regulatory Information for acitretin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan | ACITRETIN | acitretin | CAPSULE;ORAL | 202148-001 | Sep 10, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Impax Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 202552-004 | Dec 23, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Impax Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 202552-001 | Dec 23, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Impax Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 202552-003 | Dec 23, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.